Skip to main content

Table 3 Sensitivity and specificity for colorectal cancer and significant colonic lesion of the prediction model at the thresholds with 90 % (5.6) and 99 % (3.5) sensitivity for colorectal cancer detection in the derivation and validation cohorts

From: Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients

COLONPREDICT score

≥5.6

≥3.5

Sensitivitya

Specificitya

Sensitivitya

Specificitya

CRC

Derivation

90.1 % (85.1–93.6)

78.7 % (76.4–80.9)

99.5 % (97.0–100.0)

45.8 % (43.1–48.2)

Validation

87.1 % (79.9–92.1)

79.3 % (76.9–81.4)

100 % (96.0–100.0)

46.8 % (44.0–49.6)

pb

0.4

0.7

1

0.6

ANc

Derivation

66.7 % (61.8–71.2)

82.3 % (79.9–84.4)

89.5 % (86.1–92.2)

50.1 % (47.2–53.1)

Validation

66.0 % (60.3–71.3)

83.5 % (81.2–85.7)

88.2 % (83.9–91.5)

50.7 % (47.7–53.7)

pb

0.8

0.4

0.6

0.8

SCLd

Derivation

64.2 % (59.5–68.5)

83.1 % (80.7–85.2)

88.7 % (85.3–91.4)

51.3 % (48.3–54.3)

Validation

59.2 % (53.9–64.3)

84.2 % (81.8–86.3)

84.7 % (80.5–88.2)

51.8 % (48.7–54.9)

pb

0.1

0.5

0.09

0.8

  1. aValues are expressed as the percentage and its 95 % confidence interval
  2. bSignificance of the sensitivity and specificity differences between both cohorts in the Chi-square test. Differences with p < 0.05 are considered statistically significant
  3. cColorectal cancer, advanced adenoma (≥10 mm, villous histology, high-grade dysplasia)
  4. dColorectal cancer, advanced adenoma (≥10 mm, villous histology, high-grade dysplasia), polyposis (>10 polyps of any histology), colitis (any aetiology), polyps ≥10 mm, complicated diverticular disease, colonic ulcer and/or bleeding angiodysplasia
  5. AN advanced neoplasia, CRC colorectal cancer, SCL significant colonic lesion